Lewes, DE -- (SBWire) -- 08/22/2018 --Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.
The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response.
OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 2, 5 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hematological Tumor, Hepatitis B, Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Spanning over 71 pages "Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018" report covers Introduction, Report Coverage, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles, Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products, Appendix. This report Covered Companies - AbbVie Inc, Abeome Corp, Alligator Bioscience AB, Apogenix AG, BioInvent International AB, Bristol-Myers Squibb Co, Denceptor Therapeutics Ltd, GigaGen Inc, GlaxoSmithKline Plc, Incyte Corp, Innovent Biologics Inc, Invenra Inc, Kyowa Hakko Kirin Co Ltd, MedImmune LLC, Pfizer Inc, Zai Lab Ltd.
Please visit this link for more details: https://www.marketresearchreports.com/global-markets-direct/tumor-necrosis-factor-receptor-superfamily-member-4-act35-antigen-or-tax-3
Find all Drug Pipeline Reports at: https://www.marketresearchreports.com/drug-pipeline
For related reports please visit: https://www.marketresearchreports.com/search/site/Tumor%2520Necrosis%2520Factor
Read our Interactive Market Research Blog
About MarketResearchReprots.com
MarketResearchReprots.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Contact us for your market research requirements: https://www.marketresearchreports.com/contact
